Journal of Pharmacokinetics and Pharmacodynamics

, Volume 46, Issue 6, pp 511–512 | Cite as

Journal editor’s final report

  • William J. JuskoEmail author

The Journal of Pharmacokinetics and Biopharmaceutics (JPB) was established by Founding Editor Sidney Riegelman along with Leslie Benet and Malcolm Rowland in 1973 in response to the early growth of these scientific disciplines and to serve as a forum for describing innovations in modeling methodology and applications. The editors stated, “The journal will be devoted to illustrating the importance of pharmacokinetics and biopharmaceutics in the understanding of the mechanisms of drug action, design, therapy, and evaluation”. The first volume included a seminal article describing clearance concepts [1] and I was pleased that my early efforts in modeling chemotherapeutic effects appeared as well [2]. (My first of 65 publications in the Journal.) The name was changed in 2001 to the Journal of Pharmacokinetics and Pharmacodynamics (JPKPD) as the latter area was expanding and “to recognize the rapid growth in the number of Journal articles that deal with the overall time-course of drug action”.

The inside cover of the Journal lists the Editors Emeritus. I joined as Co-Editor in 2005. The Editors, Associate Editors, and the Editorial Advisory Boards have included highly prominent international scientists who have also contributed strongly to JPKPD as reviewers and authors.

Figure 1 depicts the publication rates in JPB and JPKPD over the time frame of existence of the journal. The marked increases that have occurred during the past 15 years can be attributed to several factors. Most importantly, the publication rates reflect the general growth of the related areas of PKPD, pharmacometrics, and quantitative systems pharmacology. In 2005 there was a transition from submissions and reviews on paper and through the mail to the present on-line system (Editorial Manager). In 2010 the cover was modified (designed by Amanda Almon) and model diagrams were featured (and likely framed and evident on office walls). In 2012 the page format was increased to the current 8.25- × 11-inch size with condensed type fonts and new style providing more easily viewed information. Since 2012, JPKPD has been an “official journal” of the International Society of Pharmacometrics. Extremely helpful have been a series of ‘Special Issues’ of JPKPD, some with Guest Editors, that have either honored a prominent scientist or reflected a focus area in PKPD. The most recent Impact Factor is 2.91, a reasonable value for a small niche journal with considerable competition in the field of pharmacology.
Fig. 1

Journal publication history

I have been extremely appreciative of the assistance of Associate Editors Mats Karlsson since 2008 and Peter Bonate since 2012. Suzette Mis has assisted immensely as Journal Secretary since 2007. Mats has numerous seminal pharmacometric methodology articles and Pete has provided highly regarded Special Issues of JPKPD over the past several years in addition to their looking after many manuscript submissions. I am extremely pleased that Pete has agreed to continue serving the Journal and ISoP as Editor-in-Chief. His broad knowledge of PKPD and pharmacometric methodology as reflected in his excellent textbook [3] and his creative insights into communicating modeling results [4] will help continue to serve the authors and readers extremely well.

Serving as Editor-in-Chief of JPKPD has been immensely satisfying for me as the journal not only continues to publish innovative modeling methodology in the field, but has expanded its array of articles in pharmacometrics and mathematical pharmacology. I have been pleased to interact with the Editorial Advisory Board and numerous authors and reviewers to help produce highly interesting and insightful publications that reflect the state-of-the-art.



  1. 1.
    Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokin Biopharm 1:123–136CrossRefGoogle Scholar
  2. 2.
    Jusko WJ (1973) A pharmacodynamic model for cell-cycle specific chemotherapeutic agents. J Pharmacokin Biopharm 1:175–200CrossRefGoogle Scholar
  3. 3.
    Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation, 2nd edn. Springer, New YorkCrossRefGoogle Scholar
  4. 4.
    Bonate PL (2014) Be a model communicator: and sell your models to anyoneGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.State University of New York at BuffaloDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical SciencesBuffaloUSA

Personalised recommendations